Novavax
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The compa...
Latest News
5 days ago · prnewswire.com
Novavax to Participate in Jefferies London Healthcare ConferenceGAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference, London, United KingdomFireside chat on Tuesday, November 17, 2026, at 5:00 p.m.
6 days ago · zacks.com
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItZacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
11 days ago · zacks.com
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs DeclineNovavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
11 days ago · marketbeat.com
Novavax Q3 Earnings Call HighlightsNovavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.
12 days ago · seekingalpha.com
Novavax, Inc. (NVAX) Q3 2026 Earnings Call TranscriptNovavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Novavax (NVAX) Reports Q3 Loss, Tops Revenue EstimatesNovavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
12 days ago · prnewswire.com
Novavax Reports Third Quarter 2026 Financial Results and Operational HighlightsReports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027 Multiple Novavax and partner-led experiments with Matrix-M ® currently underway in a wide array of infectious disease targets and oncology models Company to host conference call today at 8:30 a.m.
19 days ago · zacks.com
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseNovavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
19 days ago · prnewswire.com
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeThe global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
19 days ago · prnewswire.com
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NVAX